胰腺癌的性别、种族和民族差异：PRECEDE 联盟的结果和影响。
Pancreatic Cancer Disparities among Gender, Race, and Ethnicity: The PRECEDE Consortium Outcomes and Impact.
机构信息
Center for Cancer Prevention and Drug Development (CCPDD), Stephenson Cancer Center (SCC), Department of Internal Medicine, Hematology/Oncology Section, University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, Oklahoma.
VA Medical Center, Oklahoma City, Oklahoma.
出版信息
Cancer Prev Res (Phila). 2023 Jun 1;16(6):305-307. doi: 10.1158/1940-6207.CAPR-23-0086.
The Pancreatic Cancer Early Detection (PRECEDE) Consortium was launched internationally to assess the surveillance of high-risk individuals (HRI) of pancreatic cancer, focusing on genetic risk factors. In the early recruitment period of 3 years from May 2020 to March 2022, the PRECEDE gathered analysis-eligible data on 1,113 HRIs. In this issue of Cancer Prevention Research, Katona and colleagues reported current portrait of demographics of the participants, with significant disparities in gender, race and ethnicity. Now the PRECEDE Consortium aims at correcting these disparities in the next 3 years and double the percentage of underrepresented groups to more closely represent the demographics of patients. See related article by Katona et al., p. 343.
胰腺癌早期检测（PRECEDE）联盟在国际上成立，旨在评估胰腺癌高危个体（HRI）的监测，重点是遗传风险因素。在 2020 年 5 月至 2022 年 3 月的早期招募期内，PRECEDE 收集了 1113 名 HRI 的可分析数据。在本期《癌症预防研究》中，Katona 及其同事报告了参与者的人口统计学现状，在性别、种族和民族方面存在显著差异。现在，PRECEDE 联盟的目标是在未来 3 年内纠正这些差异，并将代表性不足群体的比例提高一倍，以更接近患者的人口统计学特征。见 Katona 等人的相关文章，第 343 页。
Zotero 插件